Obese men who are diagnosed with prostate cancer have more than two-and-a-half times the risk of dying from the disease as compared to men of normal weight at the time of diagnosis, according to a study by researchers at Fred Hutchinson Cancer Research Center. The findings by senior author Alan Kristal, Dr.P.H., and colleagues appear online and will be published in the March 15 print edition of the journal Cancer.
"I was very surprised by the findings," said Kristal, member and associate head of the Cancer Prevention Program in the
"If a man is obese at the time of diagnosis, he faces a 2.6-fold greater risk of dying as compared to a normal-weight man with the same diagnostic profile, regardless of whether he has a radical prostatectomy or radiation therapy, whether or not he gets androgen-deprivation therapy, whether he has low- or high-grade disease and whether he has localized, regional or distant disease," Kristal said, referring to the degree of cancer spread.
The researchers also found that obese men diagnosed with local or regional disease -- that is, disease that is confined to the prostate or has spread to into surrounding tissue -- face a 3.6-fold increased risk of cancer spreading into distant organs, or metastasis, as compared to prostate-cancer patients of normal weight. The association of obesity with disease progression was strongest among men with regional stage at diagnosis, whose cancer had already spread beyond the prostate, as compared to men with early, localized disease.
The mechanisms behind the link between obesity and prostate cancer metastasis and death are believed to involve both steroid hormones and inflammation. "We are now beginning to appreciate that obesity is a massive inflammatory condition," Kristal said, "and obesity also increases levels of serum estrogens and growth factors that can promote cancer growth."
For the study, Kristal, first author Zhihong Gong, Ph.D., a postdoctoral research fellow in the
Only one other study has examined obesity and prostate-cancer outcome; this study reported no association between the two, but the study was limited to men at one hospital, all of whom received radical prostatectomy.
Kristal's study is the first long-term, population-based study of prostate-cancer patients who have undergone a variety of treatments. A strength of the study is that it used metastasis and mortality as an endpoint versus biochemical recurrence (the presence of circulating prostate-specific antigen, or PSA, in the blood after treatment, a biomarker of limited value in predicting death from prostate cancer).
"I think this study represents the first good piece of evidence that losing weight may in fact reduce the risk of dying of prostate cancer," Kristal said. "Although one would need a randomized clinical trial to definitively determine whether weight loss could be an effective complimentary treatment for obese men diagnosed with prostate cancer, these results offer yet another good reason for men to achieve and maintain a healthy weight," he said.
The National Institutes of Health, the National Cancer Institute and